Clinical Trials Logo

Refractory B-Cell Lymphoma clinical trials

View clinical trials related to Refractory B-Cell Lymphoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT06378190 Recruiting - Clinical trials for B-cell Lymphoma Recurrent

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

TranspoCART19
Start date: March 11, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to to evaluate the safety and efficacy of TranspoCART19 in patients with relapsed/refractory B-lymphoma. The main questions it aims to answer are: Maximum tolerated dose (MTD) Response rates Participants will be treated with the investigational medicinal product and will be followed for 36 months.

NCT ID: NCT06158386 Recruiting - Follicular Lymphoma Clinical Trials

Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma

Start date: November 22, 2023
Phase: Phase 2
Study type: Interventional

To observe the safety and efficacy of Chidamide combined with Linperlisib in the treatment of refractory and relapsed follicular lymphoma.

NCT ID: NCT05003141 Recruiting - Clinical trials for Mantle Cell Lymphoma

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Start date: November 15, 2021
Phase: Phase 1
Study type: Interventional

Product: PSB202 is a novel biological entity consisting of two engineered monoclonal antibodies, an Fc-enhanced humanized type II anti-CD20 IgG1 (PSB102) and a humanized anti-CD37 IgG1 (PSB107), that target B-cells. PSB202 is manufactured to work as a single product with the two components of PSB202 enabling a distinct dual target-specific antibody directed cell killing of B-cells. Study: Multi-center-, International Phase 1a/1b (Escalation/Expansion) study in patients with indolent-, relapsed-, B-cell malignancies. The Phase 1a (Dose Escalation) part of study follows a 3+3 design.

NCT ID: NCT04300998 Recruiting - Multiple Myeloma Clinical Trials

Study of CAR-T Therapy in Older Patients

Start date: March 4, 2020
Phase:
Study type: Observational

This study is being done to find out how older patients respond to CAR-T cell therapy and how the treatment affects their quality of life. This is a quality of life study and participating in the study does not involve receiving any treatment, other than the standard treatment for participants' disease.

NCT ID: NCT03824964 Not yet recruiting - Clinical trials for Refractory B-Cell Lymphoma

Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Start date: February 1, 2019
Phase: Early Phase 1
Study type: Interventional

This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD19/CD22 CAR NK cells in patients with relapsed refractory B cell lymphoma.

NCT ID: NCT03824951 Not yet recruiting - Clinical trials for Refractory B-Cell Lymphoma

Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Start date: February 1, 2019
Phase: Early Phase 1
Study type: Interventional

This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD19 iCAR NK cells in patients with relapsed refractory B cell lymphoma.

NCT ID: NCT03692767 Not yet recruiting - Clinical trials for Refractory B-Cell Lymphoma

Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Start date: March 2019
Phase: Early Phase 1
Study type: Interventional

This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD22 CAR NK cells in patients with relapsed refractory B cell lymphoma.

NCT ID: NCT03690310 Not yet recruiting - Clinical trials for Refractory B-Cell Lymphoma

Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Start date: March 2019
Phase: Early Phase 1
Study type: Interventional

This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD19 CAR NK cells in patients with relapsed refractory B cell lymphoma.